Cempra Inc (CEMP) 8.78 $CEMP
Cempra to Present Data on Solithromycin at ECCMID Highlighting Potential New Indications, Safety and Activity Spectrum
GlobeNewswire - Fri May 09, 6:00PM CDT
Cempra, Inc. (Nasdaq:CEMP) today announced that it will present data at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain, that continue to enhance the profile of solithromycin in regards to potential new indications, safety and spectrum of activity particularly against contemporary strains. Presentations will occur on Saturday, May 10 to Tuesday, May 13.
Cempra, Inc. to Present at Three Investor Conferences
GlobeNewswire - Thu May 08, 3:00PM CDT
Cempra, Inc. (Nasdaq: CEMP) today announced that Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will present at three upcoming investor conferences.
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014: 76 Companies and 141 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/d62n92/methicillinresist) has announced the addition of the "Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved in Therapeutics Development - AIMM Therapeutics B.V. - Absynth Biologics Limited - Agilvax, Inc. - Alchemia Limited - AmpliPhi Biosciences Corporation - Aphios Corporation - Aridis Pharmaceuticals LLC - Basilea Pharmaceutica AG - Bharat Biotech International Limited - Biota Pharmaceuticals, Inc. - Cantab Biopharmaceuticals Limited - Cellceutix Corporation - Cempra, Inc. - ConjuGon, Inc. - ContraFect Corporation - CrystalGenomics, Inc. - Cubist Pharmaceuticals, Inc. - DesignMedix, Inc. - Destiny Pharma Ltd. - Dong-A Socio Holdings Co Ltd - Durata Therapeutics, Inc. - Eli Lilly and Company - Enanta Pharmaceuticals, Inc. - Ensoltek Co., Ltd. - Evolva SA - Excelimmune, Inc. - Galapagos NV - GangaGen Inc. - Genentech, Inc. - Helix BioMedix, Inc.. Drug Profiles - oritavancin disphosphate - ceftobiprole medocaril - vancomycin hydrochoride - oritavancin disphosphate - tedizolid phosphate - HT-61 - omadacycline tosylate - brilacidin - TD-1792 - AR-301 - XF-73 - CG-400549 - WCK-771 - MRX-I - levonadifloxacin - vancomycin - LTX-109 - P-128 - dalbavancin - ceftaroline fosamil - lotilibcin - BC-7013 - MRX-I - NDV-3 Vaccine - SASPject PT1.2 - KRPAM-1977X - KRPAM-1977Y - EDP-788 - SAL-200 - LCB-010371 For more information visit http://www.researchandmarkets.com/research/d6...llinresist
Cempra Presents Late-Breaker on Solithromycin's Anti NASH Effects in an Animal Model at DDW 2014
GlobeNewswire - Tue May 06, 9:15AM CDT
Cempra, Inc., (Nasdaq:CEMP) today announced a late-breaker presentation demonstrating that solithromycin significantly reduced ballooning degeneration and inflammation which are histological signs of non-alcoholic steatohepatitis (NASH) in an animal model at Digestive Disease Week (DDW) in Chicago. The abstract titled, "Anti-NASH Effects of Solithromycin in NASH-HCC Mouse Model," will be presented at 9:15 a.m. CDT, Tuesday, May 6, in Room S015A at McCormick Place in Chicago.
Is Cempra (CEMP) Ready to Breakout? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 01, 6:14AM CDT
Is Cempra (CEMP) Ready to Breakout?
Cempra, Inc. Reports First Quarter 2014 Financial and Operating Results
GlobeNewswire - Tue Apr 29, 3:00PM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the first quarter ended March 31, 2014. The company will host a conference call and webcast at 4:30 p.m. EDT, today.
Global Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics Pipeline Review 2014
M2 - Tue Apr 29, 8:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s3gfs5/reflux) has announced the addition of the "Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastroesophageal Reflux Disease) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Reflux Esophagitis (Gastroesophageal Reflux Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Johnson & Johnson - Takeda Pharmaceutical Company Limited - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Wockhardt Limited - Shire Plc - Flamel Technologies S.A. - Yuhan Corporation - Torrent Pharmaceuticals Limited - Ahn-Gook Pharmaceutical Co., Ltd. - aRigen Pharmaceuticals, Inc. - Cempra, Inc. - Vecta Ltd. - Sihuan Pharmaceutical Holdings Group Ltd. - Reviva Pharmaceuticals Inc. - RaQualia Pharma Inc. - Rottapharm|Madaus - Armetheon, Inc. For more information visit http://www.researchandmarkets.com/research/s3gfs5/reflux
Cempra, Inc. to Report First Quarter 2014 Financial and Operating Results, and Host Conference Call and Webcast on April 29, 2014
GlobeNewswire - Tue Apr 22, 3:18PM CDT
Cempra, Inc. (Nasdaq:CEMP) today announced that it will report first quarter 2014 financial results and provide a business update after the close of U.S. financial markets on April 29, 2014. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra will host a conference call and webcast at 4:30 p.m. EDT, April 29, 2014.
Emerging 'Superbugs' -- and Why Investors Should Care
at The Street - Mon Apr 21, 11:23AM CDT
Antibiotic-resistant 'superbugs' are spreading, and drug companies and their investors should take notice.
Treatments for Non-Alcoholic Steatohepatitis Making Clinical Strides
ACCESSWIRE - Tue Apr 08, 10:00AM CDT
WHITEFISH, MT / April 8, 2014 / There has been a disease steadily filling market headlines recently, and no; it's not cancer. It's fatty liver disease, particularly Non-alcoholic Fatty Liver Disease, or NAFLD, regarded by many as the most common non-communicable liver disease worldwide. The disease is a silent killer that often goes undetected until late stages, for which there are no FDA-approved treatments. Biotechs focusing on innovative therapies for varying stages of NAFLD are receiving plenty of deserved media coverage. Hepatology leaders in recent headlines include Intercept Pharmaceuticals, (NASDAQ: ICPT), Cempra, Inc. (NASDAQ: CEMP), MediciNova, Inc. (NASDAQ: MNOV), Galectin Therapeutics (NASDAQ: GALT) and Lumena Pharmaceuticals, a company preparing to go public.
Cempra's Solithromycin Demonstrates Therapeutic Potential Beyond Anti-Bacterial Activity
GlobeNewswire - Thu Apr 03, 3:05PM CDT
Cempra, Inc. (Nasdaq:CEMP) today announced the presentation of a late-breaking abstract entitled "Anti-NASH Effects of Solithromycin in NASH-HCC Mouse Model," at 9:15 a.m. EDT, May 6, at Digestive Disease Week (DDW(R)) 2014 in Room S105A at McCormick Place in Chicago. The presentation will be included in the session entitled "Basic Late Breaking Abstract Session."
Tetraphase Antibiotic Nearing Key Tolerability Test
at The Street - Wed Apr 02, 7:00AM CDT
The lead-in phase of a phase III study will tell us a lot about whether Tetraphase's eravacycline antibiotic can be administered orally.
Cempra to Present Late-Breaker on Solithromycin Reducing Inflammation in an Animal Model for Cancer Chemotherapy-Induced Lung Injury
GlobeNewswire - Thu Mar 27, 7:14AM CDT
Study Suggests Clinical Uses of Solithromycin Beyond Bacterial Infections
Cempra, Inc. to Present at The 21st Annual Future Leaders in the Biotech Industry Conference and Needham & Co. 12th Annual Healthcare Conference
GlobeNewswire - Thu Mar 20, 3:12PM CDT
Cempra, Inc. (Nasdaq:CEMP) today announced that Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will present at The 21 Annual Future Leaders in the Biotech Industry Conference at 11:30 a.m. EDT, Friday, March 28, at the Millennium Broadway Hotel & Conference Center in New York City and at the Needham & Co. 12 Annual Healthcare Conference at 12:50 p.m. EDT, Wednesday, April 9, at The Westin New York Grand Central in New York City. Dr. Fernandes will discuss the company's two differentiated antibiotics, solithromycin (CEM-101) for community-acquired bacterial pneumonia and TAKSTA (CEM-102 or fusidic acid) for the chronic, oral treatment of Gram-positive pathogens including methicillin-resistant S. aureus (MRSA) in prosthetic joint infections.
What Falling Estimates & Price Mean for Cempra (CEMP) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 7:45AM CDT
Cempra has witnessed a significant price decline in the past four weeks. The reason is negative trend in earnings estimate revisions. The stock also has seen some pretty dismal trading lately.
Cempra, Inc. to Present at Barclays Capital 2014 Global Healthcare Conference and 26th Annual ROTH Conference
GlobeNewswire - Fri Mar 07, 2:58AM CST
Cempra, Inc. (Nasdaq:CEMP) today announced that Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will present at the Barclays Capital 2014 Global Healthcare Conference at 3:45 p.m. EST, Wednesday, March 12, at the Loews Miami Hotel in Miami Beach, Fla. and at the 26 Annual ROTH Conference at 3:30 p.m. PST, Monday, March 10, at The Ritz Carlton in Laguna Niguel, Calif. Dr. Fernandes will discuss the company's two differentiated antibiotics, solithromycin (CEM-101) for community-acquired bacterial pneumonia and TAKSTA (CEM-102 or fusidic acid) for the chronic, oral treatment of Gram-positive pathogens including methicillin-resistant S. aureus (MRSA) in prosthetic joint infections.
Cempra (CEMP) Falls: Stock Plunges 12.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 7:35AM CST
The shares of Cempra fell over 12% on the day. This breaks the recent trend of the company, as the stock is now trading within the volatile price range of $11.2 to $13.7 in the past one-month time frame. This pharmaceutical company has seen a flat track record when it comes to current year estimate revisions.
Nasdaq stocks posting largest percentage decreases
AP - Fri Feb 28, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Cempra, Inc. Reports Fourth Quarter and Full Year 2013 Financial and Operating Results
GlobeNewswire - Thu Feb 27, 3:14PM CST
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the fourth quarter and full year ended Dec. 31, 2013. The company will host a conference call and webcast at 4:30 p.m. EST, today.
Cempra to Present Data on Solithromycin at ECCMID Highlighting Potential New Indications, Safety and Activity Spectrum
GlobeNewswire - Fri May 09, 6:00PM CDT
Cempra, Inc. (Nasdaq:CEMP) today announced that it will present data at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain, that continue to enhance the profile of solithromycin in regards to potential new indications, safety and spectrum of activity particularly against contemporary strains. Presentations will occur on Saturday, May 10 to Tuesday, May 13.
Cempra, Inc. to Present at Three Investor Conferences
GlobeNewswire - Thu May 08, 3:00PM CDT
Cempra, Inc. (Nasdaq: CEMP) today announced that Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will present at three upcoming investor conferences.
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014: 76 Companies and 141 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/d62n92/methicillinresist) has announced the addition of the "Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved in Therapeutics Development - AIMM Therapeutics B.V. - Absynth Biologics Limited - Agilvax, Inc. - Alchemia Limited - AmpliPhi Biosciences Corporation - Aphios Corporation - Aridis Pharmaceuticals LLC - Basilea Pharmaceutica AG - Bharat Biotech International Limited - Biota Pharmaceuticals, Inc. - Cantab Biopharmaceuticals Limited - Cellceutix Corporation - Cempra, Inc. - ConjuGon, Inc. - ContraFect Corporation - CrystalGenomics, Inc. - Cubist Pharmaceuticals, Inc. - DesignMedix, Inc. - Destiny Pharma Ltd. - Dong-A Socio Holdings Co Ltd - Durata Therapeutics, Inc. - Eli Lilly and Company - Enanta Pharmaceuticals, Inc. - Ensoltek Co., Ltd. - Evolva SA - Excelimmune, Inc. - Galapagos NV - GangaGen Inc. - Genentech, Inc. - Helix BioMedix, Inc.. Drug Profiles - oritavancin disphosphate - ceftobiprole medocaril - vancomycin hydrochoride - oritavancin disphosphate - tedizolid phosphate - HT-61 - omadacycline tosylate - brilacidin - TD-1792 - AR-301 - XF-73 - CG-400549 - WCK-771 - MRX-I - levonadifloxacin - vancomycin - LTX-109 - P-128 - dalbavancin - ceftaroline fosamil - lotilibcin - BC-7013 - MRX-I - NDV-3 Vaccine - SASPject PT1.2 - KRPAM-1977X - KRPAM-1977Y - EDP-788 - SAL-200 - LCB-010371 For more information visit http://www.researchandmarkets.com/research/d6...llinresist
Cempra Presents Late-Breaker on Solithromycin's Anti NASH Effects in an Animal Model at DDW 2014
GlobeNewswire - Tue May 06, 9:15AM CDT
Cempra, Inc., (Nasdaq:CEMP) today announced a late-breaker presentation demonstrating that solithromycin significantly reduced ballooning degeneration and inflammation which are histological signs of non-alcoholic steatohepatitis (NASH) in an animal model at Digestive Disease Week (DDW) in Chicago. The abstract titled, "Anti-NASH Effects of Solithromycin in NASH-HCC Mouse Model," will be presented at 9:15 a.m. CDT, Tuesday, May 6, in Room S015A at McCormick Place in Chicago.
Is Cempra (CEMP) Ready to Breakout? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 01, 6:14AM CDT
Is Cempra (CEMP) Ready to Breakout?
Cempra, Inc. Reports First Quarter 2014 Financial and Operating Results
GlobeNewswire - Tue Apr 29, 3:00PM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the first quarter ended March 31, 2014. The company will host a conference call and webcast at 4:30 p.m. EDT, today.
Global Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics Pipeline Review 2014
M2 - Tue Apr 29, 8:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s3gfs5/reflux) has announced the addition of the "Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastroesophageal Reflux Disease) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Reflux Esophagitis (Gastroesophageal Reflux Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Johnson & Johnson - Takeda Pharmaceutical Company Limited - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Wockhardt Limited - Shire Plc - Flamel Technologies S.A. - Yuhan Corporation - Torrent Pharmaceuticals Limited - Ahn-Gook Pharmaceutical Co., Ltd. - aRigen Pharmaceuticals, Inc. - Cempra, Inc. - Vecta Ltd. - Sihuan Pharmaceutical Holdings Group Ltd. - Reviva Pharmaceuticals Inc. - RaQualia Pharma Inc. - Rottapharm|Madaus - Armetheon, Inc. For more information visit http://www.researchandmarkets.com/research/s3gfs5/reflux
Cempra, Inc. to Report First Quarter 2014 Financial and Operating Results, and Host Conference Call and Webcast on April 29, 2014
GlobeNewswire - Tue Apr 22, 3:18PM CDT
Cempra, Inc. (Nasdaq:CEMP) today announced that it will report first quarter 2014 financial results and provide a business update after the close of U.S. financial markets on April 29, 2014. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra will host a conference call and webcast at 4:30 p.m. EDT, April 29, 2014.
Emerging 'Superbugs' -- and Why Investors Should Care
at The Street - Mon Apr 21, 11:23AM CDT
Antibiotic-resistant 'superbugs' are spreading, and drug companies and their investors should take notice.
Treatments for Non-Alcoholic Steatohepatitis Making Clinical Strides
ACCESSWIRE - Tue Apr 08, 10:00AM CDT
WHITEFISH, MT / April 8, 2014 / There has been a disease steadily filling market headlines recently, and no; it's not cancer. It's fatty liver disease, particularly Non-alcoholic Fatty Liver Disease, or NAFLD, regarded by many as the most common non-communicable liver disease worldwide. The disease is a silent killer that often goes undetected until late stages, for which there are no FDA-approved treatments. Biotechs focusing on innovative therapies for varying stages of NAFLD are receiving plenty of deserved media coverage. Hepatology leaders in recent headlines include Intercept Pharmaceuticals, (NASDAQ: ICPT), Cempra, Inc. (NASDAQ: CEMP), MediciNova, Inc. (NASDAQ: MNOV), Galectin Therapeutics (NASDAQ: GALT) and Lumena Pharmaceuticals, a company preparing to go public.
Cempra's Solithromycin Demonstrates Therapeutic Potential Beyond Anti-Bacterial Activity
GlobeNewswire - Thu Apr 03, 3:05PM CDT
Cempra, Inc. (Nasdaq:CEMP) today announced the presentation of a late-breaking abstract entitled "Anti-NASH Effects of Solithromycin in NASH-HCC Mouse Model," at 9:15 a.m. EDT, May 6, at Digestive Disease Week (DDW(R)) 2014 in Room S105A at McCormick Place in Chicago. The presentation will be included in the session entitled "Basic Late Breaking Abstract Session."
Tetraphase Antibiotic Nearing Key Tolerability Test
at The Street - Wed Apr 02, 7:00AM CDT
The lead-in phase of a phase III study will tell us a lot about whether Tetraphase's eravacycline antibiotic can be administered orally.
Cempra to Present Late-Breaker on Solithromycin Reducing Inflammation in an Animal Model for Cancer Chemotherapy-Induced Lung Injury
GlobeNewswire - Thu Mar 27, 7:14AM CDT
Study Suggests Clinical Uses of Solithromycin Beyond Bacterial Infections
Cempra, Inc. to Present at The 21st Annual Future Leaders in the Biotech Industry Conference and Needham & Co. 12th Annual Healthcare Conference
GlobeNewswire - Thu Mar 20, 3:12PM CDT
Cempra, Inc. (Nasdaq:CEMP) today announced that Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will present at The 21 Annual Future Leaders in the Biotech Industry Conference at 11:30 a.m. EDT, Friday, March 28, at the Millennium Broadway Hotel & Conference Center in New York City and at the Needham & Co. 12 Annual Healthcare Conference at 12:50 p.m. EDT, Wednesday, April 9, at The Westin New York Grand Central in New York City. Dr. Fernandes will discuss the company's two differentiated antibiotics, solithromycin (CEM-101) for community-acquired bacterial pneumonia and TAKSTA (CEM-102 or fusidic acid) for the chronic, oral treatment of Gram-positive pathogens including methicillin-resistant S. aureus (MRSA) in prosthetic joint infections.
What Falling Estimates & Price Mean for Cempra (CEMP) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 7:45AM CDT
Cempra has witnessed a significant price decline in the past four weeks. The reason is negative trend in earnings estimate revisions. The stock also has seen some pretty dismal trading lately.
Cempra, Inc. to Present at Barclays Capital 2014 Global Healthcare Conference and 26th Annual ROTH Conference
GlobeNewswire - Fri Mar 07, 2:58AM CST
Cempra, Inc. (Nasdaq:CEMP) today announced that Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will present at the Barclays Capital 2014 Global Healthcare Conference at 3:45 p.m. EST, Wednesday, March 12, at the Loews Miami Hotel in Miami Beach, Fla. and at the 26 Annual ROTH Conference at 3:30 p.m. PST, Monday, March 10, at The Ritz Carlton in Laguna Niguel, Calif. Dr. Fernandes will discuss the company's two differentiated antibiotics, solithromycin (CEM-101) for community-acquired bacterial pneumonia and TAKSTA (CEM-102 or fusidic acid) for the chronic, oral treatment of Gram-positive pathogens including methicillin-resistant S. aureus (MRSA) in prosthetic joint infections.
Cempra (CEMP) Falls: Stock Plunges 12.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 7:35AM CST
The shares of Cempra fell over 12% on the day. This breaks the recent trend of the company, as the stock is now trading within the volatile price range of $11.2 to $13.7 in the past one-month time frame. This pharmaceutical company has seen a flat track record when it comes to current year estimate revisions.
Nasdaq stocks posting largest percentage decreases
AP - Fri Feb 28, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Cempra, Inc. Reports Fourth Quarter and Full Year 2013 Financial and Operating Results
GlobeNewswire - Thu Feb 27, 3:14PM CST
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the fourth quarter and full year ended Dec. 31, 2013. The company will host a conference call and webcast at 4:30 p.m. EST, today.
